"Is it time for personalised medicine for Ameloblastoma?": A hypothesis
Bhaskar Narayan1, Somesh Kumar2, Priya Kumar1
1Department of Oral and Maxillofacial Pathology and Microbiology, Maulana Azad Institute of Dental Sciences, New Delhi, Delhi, India.
Journal of Oral and Maxillofacial Pathology : JOMFP
|February 2, 2024
Abstract:
Ameloblastoma is a benign odontogenic tumor that is locally destructive. The most common treatment option is surgery, which often results in disfigurement of the face. BRAFV600E is the common gene mutation associated with its pathogenesis. Therefore, this paper hypothesizes the use of targeted drug therapy against this mutated gene.


